{"entity":{"id":"nct06060613","kind":"trial","name":"Safety and Efficacy of OBX-115 in Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of OBX-115 in melanoma and non-small-cell lung cancer, run by Obsidian Therapeutics, Inc., now recruiting.","summary":"Safety and Efficacy of OBX-115 in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06060613 by Obsidian Therapeutics, Inc., with 208 participants planned, started 2023-10-25 and due to reach its primary completion in 2029-06-30. Interventions recorded: OBX-115.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06060613","url":"https://clinicaltrials.gov/study/NCT06060613"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["obsidian-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06060613","phase":"1/2","setting":"A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) In Participants With Advanced Solid Tumors","sponsor":"Obsidian Therapeutics, Inc.","enrolled":208,"outcomes":[]},"route":"/trials/nct06060613/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"obsidian-therapeutics","kind":"company","name":"Obsidian Therapeutics","route":"/companies/obsidian-therapeutics/"}]}}